Neurolutions CSO and Founder Dr. Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand® benefits the brain’s motor networks and also motor recovery in chronic stroke patients with extended usage.
Brain-Computer Interface – The Future of Rehabilitation
Brain-computer interface rehabilitation using the IpsiHand is associated with the functional reorganization of the brain on the uninjured side and benefits post-stroke motor recovery. Findings from these studies support that “coupling” of specific brain wave frequencies related to motor learning and skill acquisition occurred with regular BCI sessions and was strongly correlated with motor recovery outcome measures.
BCI Research
There are two new studies that provide evidence that brain-computer interface therapy with the IpsiHand has a positive impact on the brain’s motor networks in chronic stroke patients as they recover motor function after extended use. This research is specifically focused on learning how brain-computer interfaces (or BCIs) can be used to advance stroke recovery through the use of rehabilitation using BCIs.
UEFM: Upper Extremity Fugl-Meyer; AMAT: Arm Motor Ability Test; C3, C4: left and right motor electrodes.
In the first paper, it is shown how, as patients recover motor function, the brain’s fundamental electrophysiology changes, in particular its phase-amplitude coupling. Read more about the motor network reorganization with the use of brain-computer interface.
Neurolutions is a medical technology company dedicated to transforming the lives of patients suffering from neurological conditions. Our mission is to develop innovative solutions that address the unmet needs of patients while advancing the field of neurorehabilitation through cutting-edge research and development.
The IpsiHand System is a breakthrough therapeutic device that uses brain-computer interface technology to help chronic stroke patients with an impaired upper extremity regain movement. The IpsiHand device has been clinically validated and has received FDA clearance for use in the United States.
To learn more about IpsiHand, visit our Clinicians page.
About Kandu, Inc.
Kandu, Inc. is pioneering an integrated approach to stroke recovery, combining FDA-cleared brain-computer interface technology with personalized care delivery models. The company’s IpsiHand® device enables stroke survivors with upper-extremity paralysis to regain functional movement by leveraging neural intent and neuroplasticity. Kandu’s solutions are designed to extend recovery beyond the hospital, supporting improved mobility, independence, and quality of life while creating durable value for patients, providers, and investors.
For more information, visit kandu.com.
IpsiHand® is manufactured by Neurolutions, a Kandu, Inc. company.